Table 2 Regimen used as second-line treatment (N = 204)

From: Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

Content No. (%)
Induction followed by SCT 26 (12.7%)
AlloSCT 16 (7.8%)
AutoSCT 10 (4.9%)
Without SCT consolidation 178 (87.3%)
Ibrutinib-based regimen 46 (22.5%)
Ibrutinib single agent 29 (14.2%)
Ibrutinib plus chemotherapy/rituximab 9 (4.4%)
Ibrutinib plus buparlisib 8 (3.9%)
Bortezomib-based regimens 30 (14.7%)
Bortezomib single agent 14 (6.9%)
Bortezomib plus rituximab 5 (2.5%)
Rituximab, cyclophosphamide, bortezomib, and prednisone (R-CBorP) 8 (3.9%)
Bortezomib plus other chemotherapeutic agents 3 (1.5%)
Bendamustine-based regimens 30 (14.7%)
Rituximab plus bendamustine (RB) 22 (10.8%)
Bendamustine plus bortezomib plus rituximab (BBR) 5 (2.5%)
Ofatumumab plus bendamustine 1 (0.5%)
Veliparib plus bendamustine 1 (0.5%)
Bendamustine single agent 1 (0.5%)
Monoclonal antibody single agent 21 (10.3%)
CD20 antibody single agent 18 (8.8%)
CD19 antibody single agent 2 (1.0%)
ADCT-401 single agent 1 (0.5%)
Radiotherapy/surgical resection 17 (8.3%)
Radiotherapy alone 13 (6.4%)
Surgical resection alone 4 (2.0%)
Lenalidomide plus rituximab 5 (2.5%)
PI3K inhibitor single agent 2 (1.0%)
Duvelisib single agent 1 (0.5%)
Buparlisib single agent 1 (0.5%)
BCL2 inhibitor-based regimens 2 (1.0%)
Venetoclax single agent 1 (0.5%)
BCL201 plus idelalisib 1 (0.5%)
CDK 4/6 inhibitor palbociclib single agent 1 (0.5%)
HDAC inhibitor vorinostat single agent 1 (0.5%)
SYK/JAK inhibitor cerdulatinib single agent 1 (0.5%)
Other 22 (10.8%)
Other conventional chemotherapies* 21 (10.3%)
Radioimmunotherapy 1 (0.5%)
  1. SCT stem cell transplant, alloSCT allogenic SCT, AutoSCT autologous SCT
  2. Asterisk indicates other conventional chemotherapy regimens used including PC (pentostatin,cyclophosphamide) ± rituximab, N = 5; R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), N = 4; EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) ± rituximab, N = 2; ICE (ifosfamide, carboplatin, and etoposide) ± rituximab, N = 2; FC (fludarabine and cyclophosphamide) ± rituximab, N = 2; CEPP (cyclophosphamide, etoposide, procarbazine, and prednisone), N = 1; FM (fludarabine and mitoxantrone), N = 1; rituximab and methotrexate, N = 1; R-BAC (rituximab, bendamustine, and cytarabine), N = 1; rituximab and ifosfamide, N = 1; R-GCVP(gemcitabine, cyclophosphamide, vincristine, and prednisolone), N = 1